ImmunoGen Inc. (IMGN)

8.93
0.22 2.50
NASDAQ : Health Technology
Prev Close 8.71
Open 8.89
Day Low/High 8.89 / 9.19
52 Wk Low/High 4.80 / 13.41
Volume 607.42K
Avg Volume 2.03M
Exchange NASDAQ
Shares Outstanding 149.02M
Market Cap 1.32B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ImmunoGen Reports Recent Progress And Second Quarter 2018 Operating Results

ImmunoGen Reports Recent Progress And Second Quarter 2018 Operating Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported operating results for the quarter ended June 30, 2018.

ImmunoGen Announces Conference Call To Discuss Its Second Quarter 2018 Operating Results

ImmunoGen Announces Conference Call To Discuss Its Second Quarter 2018 Operating Results

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Company will host a conference call at 8:00 a.

ImmunoGen Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

ImmunoGen Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the underwriters of its previously announced public offering of common stock have exercised in full their...

IMGN Crosses Above Average Analyst Target

IMGN Crosses Above Average Analyst Target

In recent trading, shares of ImmunoGen, Inc. have crossed above the average analyst 12-month target price of $10.75, changing hands for $11.21/share.

ImmunoGen Announces FDA Fast Track Designation For Mirvetuximab Soravtansine In Patients With Platinum-Resistant Ovarian Cancer

ImmunoGen Announces FDA Fast Track Designation For Mirvetuximab Soravtansine In Patients With Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.

ImmunoGen Announces Closing Of Public Offering Of Common Stock

ImmunoGen Announces Closing Of Public Offering Of Common Stock

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the closing of its previously announced underwritten public offering of 13,700,000 shares of its common stock...

ImmunoGen Announces Pricing Of Upsized Public Offering Of Common Stock

ImmunoGen Announces Pricing Of Upsized Public Offering Of Common Stock

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the pricing of an upsized underwritten public offering of 13,700,000 shares of its common stock at a price of...

ImmunoGen Announces Proposed Public Offering Of Common Stock

ImmunoGen Announces Proposed Public Offering Of Common Stock

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that it intends to offer and sell, subject to market and other conditions, 12,000,000 shares of its common...

When the Stock Is the Only Option

When the Stock Is the Only Option

Options spreads aren't tradable with some small biotechs, making shares the only way to play.

Interesting IMGN Put And Call Options For January 2019

Investors in ImmunoGen, Inc. saw new options begin trading this week, for the January 2019 expiration.

ImmunoGen Announces Positive Findings From The FORWARD II Study Of Mirvetuximab Soravtansine Combination Regimens With Avastin® And Carboplatin In Ovarian Cancer

ImmunoGen Announces Positive Findings From The FORWARD II Study Of Mirvetuximab Soravtansine Combination Regimens With Avastin® And Carboplatin In Ovarian Cancer

ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer today announced positive data from the FORWARD II trial evaluating mirvetuximab soravtansine in multiple combination cohorts in...

ImmunoGen Reaches Analyst Target Price

In recent trading, shares of ImmunoGen, Inc. have crossed above the average analyst 12-month target price of $10.62, changing hands for $10.84/share.

ImmunoGen Reports Recent Progress And First Quarter 2018 Operating Results

ImmunoGen Reports Recent Progress And First Quarter 2018 Operating Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported operating results for the quarter ended March 31, 2018.

ImmunoGen Announces Webcast Of Presentation At Deutsche Bank's 43rd Annual Health Care Conference

ImmunoGen Announces Webcast Of Presentation At Deutsche Bank's 43rd Annual Health Care Conference

ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will present at the upcoming Deutsche Bank 43 rd Annual Health Care Conference.

Noteworthy Friday Option Activity: IMGN, HABT, STZ

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ImmunoGen, Inc. , where a total of 19,320 contracts have traded so far, representing approximately 1.9 million underlying shares.

ImmunoGen Announces Successful Completion Of Interim Analysis For FORWARD I Phase 3 Trial Of Mirvetuximab Soravtansine In Platinum-Resistant Ovarian Cancer

ImmunoGen Announces Successful Completion Of Interim Analysis For FORWARD I Phase 3 Trial Of Mirvetuximab Soravtansine In Platinum-Resistant Ovarian Cancer

ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the FORWARD I Phase 3 registration trial evaluating mirvetuximab soravtansine as a single-agent...

ImmunoGen Appoints Blaine McKee As Executive Vice President And Chief Business Officer

ImmunoGen Appoints Blaine McKee As Executive Vice President And Chief Business Officer

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Blaine McKee, Ph.

ImmunoGen Announces Conference Call To Discuss Its First Quarter 2018 Operating Results

ImmunoGen Announces Conference Call To Discuss Its First Quarter 2018 Operating Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.

ImmunoGen Presents Data From FORWARD II Assessment Of Mirvetuximab Soravtansine In Combination With Pembrolizumab At The Society Of Gynecologic Oncology Annual Meeting

ImmunoGen Presents Data From FORWARD II Assessment Of Mirvetuximab Soravtansine In Combination With Pembrolizumab At The Society Of Gynecologic Oncology Annual Meeting

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced encouraging efficacy and favorable tolerability data from the FORWARD II...

ImmunoGen Announces Presentations At AACR Annual Meeting Highlighting Continued Innovation In ADCs

ImmunoGen Announces Presentations At AACR Annual Meeting Highlighting Continued Innovation In ADCs

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three posters highlighting the Company's expertise in ADCs will be...

Walt Disney Co., RH, Immunogen: 'Mad Money' Lightning Round

Walt Disney Co., RH, Immunogen: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Walt Disney Co., RH, Immunogen, and Advanced Micro Devices.

Tech Bulls Fear China Drop: Cramer's 'Mad Money' Recap (Tuesday 3/13/18)

Tech Bulls Fear China Drop: Cramer's 'Mad Money' Recap (Tuesday 3/13/18)

In the wake of Trump's blocking the Broadcom-Qualcomm deal, Jim Cramer ask if we should be worried that all of tech that wants to be big in China could be under pressure.

ImmunoGen Reports Pipeline Progress And 2017 Operating Results

ImmunoGen Reports Pipeline Progress And 2017 Operating Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent highlights and operating results for the quarter and year ended...

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming...

ImmunoGen Announces Conference Call To Discuss Its 2017 Operating Results

ImmunoGen Announces Conference Call To Discuss Its 2017 Operating Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.

ImmunoGen Appoints Stuart A. Arbuckle To Board Of Directors

ImmunoGen Appoints Stuart A. Arbuckle To Board Of Directors

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Stuart A.

ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies

ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has been treated with IMGN632 in a Phase 1...

TheStreet Quant Rating: D (Sell)